Europe Approves Paroxysmal Nocturnal Hemoglobinuria Drug Europe Approves Paroxysmal Nocturnal Hemoglobinuria Drug

The factor D inhibitor danicopan has been approved for use in Europe for patients with paroxysmal nocturnal hemoglobinuria with residual hemolytic anemia on standard therapy.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Hematology-Oncology News Alert Source Type: news